ELI LILLY AND COMPANY (LLY) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $6.11B; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $11.66B; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $6.11B | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $6.11B |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $11.66B | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $11.66B |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | (m) | |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Amounts owed to suppliers | 6.11B USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Contract with Customer, Liability |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | Contract with Customer, Liability |
| Reported other obligations due within one year | 11.66B USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 7.34B USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $11.66B
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.11B | (m) | $11.66B | (m) | (m) | (m) | (m) | (m) | $7.34B | (m) |
| 2026-03-31 | (m) | $5.03B | (m) | $8.70B | (m) | (m) | (m) | (m) | (m) | $4.08B | (m) |
| 2025-12-31 | (m) | $5.38B | (m) | $8.46B | (m) | (m) | (m) | (m) | (m) | $3.97B | (m) |
| 2025-09-30 | (m) | $4.26B | (m) | $5.22B | (m) | (m) | (m) | (m) | (m) | $3.78B | (m) |
| 2025-06-30 | (m) | $4.08B | (m) | $5.08B | (m) | (m) | (m) | (m) | (m) | $2.34B | (m) |
| 2025-03-31 | (m) | $3.44B | (m) | $3.77B | (m) | (m) | (m) | (m) | (m) | $2.29B | (m) |
| 2024-12-31 | (m) | $3.23B | $166.30M | $5.05B | (m) | (m) | (m) | (m) | (m) | $2.18B | (m) |
| 2024-09-30 | (m) | $2.89B | $173.20M | $5.58B | (m) | (m) | (m) | (m) | (m) | $2.24B | (m) |
| 2024-06-30 | (m) | $2.92B | $180.10M | $4.25B | (m) | (m) | (m) | (m) | (m) | $2.47B | (m) |
| 2024-03-31 | (m) | $2.47B | $186.70M | $4.20B | (m) | (m) | (m) | (m) | (m) | $2.27B | (m) |
| 2023-12-31 | (m) | $2.60B | $193.60M | $3.28B | (m) | (m) | (m) | (m) | (m) | $2.24B | (m) |
| 2023-09-30 | (m) | $2.44B | $200.70M | $2.59B | (m) | (m) | (m) | (m) | (m) | $1.91B | (m) |
| 2023-06-30 | (m) | $2.47B | $211.10M | $2.27B | (m) | (m) | (m) | (m) | (m) | $1.95B | (m) |
| 2023-03-31 | (m) | $2.02B | $220.30M | $2.19B | (m) | (m) | (m) | (m) | (m) | $1.82B | (m) |
| 2022-12-31 | (m) | $1.93B | $219.20M | $2.37B | (m) | (m) | (m) | (m) | (m) | $1.74B | (m) |
| 2022-09-30 | (m) | $1.68B | $232.50M | $1.99B | (m) | (m) | (m) | (m) | (m) | $1.85B | (m) |
| 2022-06-30 | (m) | $1.66B | $242.10M | $2.00B | (m) | (m) | (m) | (m) | (m) | $1.78B | (m) |
| 2022-03-31 | (m) | $1.43B | $251.60M | $2.54B | (m) | (m) | (m) | (m) | (m) | $1.71B | (m) |
| 2021-12-31 | (m) | $1.67B | $262.60M | $3.03B | (m) | (m) | (m) | (m) | (m) | $1.64B | (m) |
| 2021-09-30 | (m) | $1.57B | $278.40M | $2.33B | (m) | (m) | (m) | (m) | (m) | $1.75B | (m) |
| 2021-06-30 | (m) | $1.60B | $270.90M | $2.62B | (m) | (m) | (m) | (m) | (m) | $1.80B | (m) |
| 2021-03-31 | (m) | $1.64B | $346.60M | $2.81B | (m) | (m) | (m) | (m) | (m) | $1.74B | (m) |
| 2020-12-31 | (m) | $1.61B | $276.80M | $2.75B | (m) | (m) | (m) | (m) | (m) | $1.71B | (m) |
| 2020-09-30 | (m) | $1.43B | $289.50M | $2.25B | (m) | (m) | (m) | (m) | (m) | $1.70B | (m) |
| 2020-06-30 | (m) | $1.25B | $299.80M | $2.06B | (m) | (m) | (m) | (m) | (m) | $1.83B | (m) |
| 2020-03-31 | (m) | $1.21B | $307.80M | $2.22B | (m) | (m) | (m) | (m) | (m) | $1.87B | (m) |
| 2019-12-31 | (m) | $1.41B | $264.60M | $2.19B | (m) | (m) | (m) | (m) | (m) | $1.01B | (m) |
| 2019-09-30 | (m) | $1.11B | $272.30M | $1.99B | (m) | (m) | (m) | (m) | (m) | $1.10B | (m) |
| 2019-06-30 | (m) | $1.20B | $277.60M | $2.19B | (m) | (m) | (m) | (m) | (m) | $1.14B | (m) |
| 2019-03-31 | (m) | $1.17B | $286.40M | $2.25B | (m) | (m) | (m) | (m) | (m) | $1.17B | (m) |
| 2018-12-31 | (m) | $1.41B | $299.30M | $2.21B | (m) | (m) | (m) | (m) | (m) | $2.84B | (m) |
| 2018-09-30 | (m) | $1.28B | $308.60M | $2.15B | (m) | (m) | (m) | (m) | (m) | $1.55B | (m) |
| 2018-06-30 | (m) | $1.32B | $315.70M | $2.19B | (m) | (m) | (m) | (m) | (m) | $1.59B | (m) |
| 2018-03-31 | (m) | $1.27B | $324.50M | $2.35B | (m) | (m) | (m) | (m) | (m) | $1.57B | (m) |
| 2017-12-31 | (m) | $1.41B | (m) | $2.83B | (m) | (m) | (m) | (m) | (m) | $1.55B | (m) |
| 2017-09-30 | (m) | $1.20B | (m) | $2.36B | (m) | (m) | (m) | (m) | (m) | $2.29B | (m) |
| 2017-06-30 | (m) | $1.26B | (m) | $2.11B | (m) | (m) | (m) | (m) | (m) | $2.44B | (m) |
| 2017-03-31 | (m) | $1.22B | (m) | $2.23B | (m) | (m) | (m) | (m) | (m) | $2.28B | (m) |
| 2016-12-31 | (m) | $1.35B | (m) | $2.22B | (m) | (m) | (m) | (m) | (m) | $2.23B | (m) |
| 2016-09-30 | (m) | $1.16B | (m) | $2.00B | (m) | (m) | (m) | (m) | (m) | $2.11B | (m) |
| 2016-06-30 | (m) | $1.21B | (m) | $2.20B | (m) | (m) | (m) | (m) | (m) | $1.91B | (m) |
| 2016-03-31 | (m) | $1.15B | (m) | $2.28B | (m) | (m) | (m) | (m) | (m) | $1.83B | (m) |
| 2015-12-31 | (m) | $1.34B | (m) | $2.46B | (m) | (m) | (m) | (m) | (m) | $1.75B | (m) |
| 2015-09-30 | (m) | $1.18B | (m) | $2.10B | (m) | (m) | (m) | (m) | (m) | $1.42B | (m) |
| 2015-06-30 | (m) | $1.15B | (m) | $2.63B | (m) | (m) | (m) | (m) | (m) | $1.45B | (m) |
| 2015-03-31 | (m) | $1.18B | (m) | $2.52B | (m) | (m) | (m) | (m) | (m) | $1.47B | (m) |
| 2014-12-31 | (m) | $1.13B | (m) | $2.47B | (m) | (m) | (m) | (m) | (m) | $1.65B | (m) |
| 2014-09-30 | (m) | $1.02B | (m) | $2.06B | (m) | (m) | (m) | (m) | (m) | $1.64B | (m) |
| 2014-06-30 | (m) | $1.12B | (m) | $2.04B | (m) | (m) | (m) | (m) | (m) | $1.84B | (m) |
| 2014-03-31 | (m) | $1.15B | (m) | $2.33B | (m) | (m) | (m) | (m) | (m) | $2.06B | (m) |
| 2013-12-31 | (m) | $1.12B | (m) | $2.33B | (m) | (m) | (m) | (m) | (m) | $1.86B | (m) |
| 2013-09-30 | (m) | $1.25B | (m) | $2.11B | (m) | (m) | (m) | (m) | (m) | $1.27B | (m) |
| 2013-06-30 | (m) | $1.14B | (m) | $2.30B | (m) | (m) | (m) | (m) | (m) | $1.26B | (m) |
| 2013-03-31 | (m) | $974.40M | (m) | $2.27B | (m) | (m) | (m) | (m) | (m) | $1.30B | (m) |
| 2012-12-31 | (m) | $1.19B | (m) | $2.74B | (m) | (m) | (m) | (m) | (m) | $1.37B | (m) |
| 2012-09-30 | (m) | $1.33B | (m) | $2.82B | (m) | (m) | (m) | (m) | (m) | $1.81B | (m) |
| 2012-06-30 | (m) | $1.20B | (m) | $2.59B | (m) | (m) | (m) | (m) | (m) | $1.47B | (m) |
| 2012-03-31 | (m) | $1.25B | (m) | $2.75B | (m) | (m) | (m) | (m) | (m) | $1.53B | (m) |
| 2011-12-31 | (m) | $1.13B | (m) | $2.90B | (m) | (m) | (m) | (m) | (m) | $1.57B | (m) |
| 2011-09-30 | (m) | $1.15B | (m) | $2.72B | (m) | (m) | (m) | (m) | (m) | $1.45B | (m) |
| 2011-06-30 | (m) | $1.19B | (m) | $2.79B | (m) | (m) | (m) | (m) | (m) | $1.55B | (m) |
| 2011-03-31 | (m) | $1.18B | (m) | $2.60B | (m) | (m) | (m) | (m) | (m) | $1.89B | (m) |
| 2010-12-31 | (m) | $1.07B | (m) | $2.65B | (m) | (m) | (m) | (m) | (m) | $1.59B | (m) |
| 2010-09-30 | (m) | $1.03B | (m) | $2.58B | (m) | (m) | (m) | (m) | (m) | $1.21B | (m) |
| 2010-06-30 | (m) | $950.30M | (m) | $2.49B | (m) | (m) | (m) | (m) | (m) | $1.11B | (m) |
| 2010-03-31 | (m) | $964.00M | (m) | $2.77B | (m) | (m) | (m) | (m) | (m) | $1.17B | (m) |
| 2009-12-31 | (m) | $968.10M | (m) | $2.68B | (m) | (m) | (m) | (m) | (m) | $1.22B | (m) |
| 2009-09-30 | (m) | $887.70M | (m) | $2.31B | (m) | (m) | (m) | (m) | (m) | $1.28B | (m) |
| 2009-06-30 | (m) | $918.60M | (m) | $2.63B | (m) | (m) | (m) | (m) | (m) | $1.33B | (m) |
| 2008-12-31 | (m) | $885.80M | (m) | $3.97B | (m) | (m) | (m) | (m) | (m) | $1.38B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |